amyloid/infarction

PRIORITY TO RELATED APPLICATIONS(S) This application claims the benefit of European Patent Application No. 08150173.6, filed Jan. 11, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of

BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of

PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No 11156587.5, filed Mar. 2, 2011, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life.

PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No. 10153843.7, filed Feb. 17, 2010, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No. 08168719.6, filed Nov. 10, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

FIELD OF THE INVENTION The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions

SUMMARY OF THE INVENTION The present invention relates to an anti-dementia agent which comprises rolipram (4-[3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) as an active ingredient. As the proportion of aged people grows larger in the society, countermeasures against senile dementia causes by

The present invention relates to compounds of formula ##STR00002## hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R.sup.1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Entry of PCT Application No. PCT/EP2017/074927, filed on Oct. 2, 2017, which is incorporated herein by reference in its entirety, which claims benefit of priority to European Application No. 16192237.2, filed on Oct. 4,

The present invention relates to a compound of formula ##STR00002## wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R.sup.1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R.sup.2 is

SUMMARY The present invention relates to compounds of formula I, ##STR00003## wherein R.sup.1 is phenyl, lower alkyl, C.sub.3-6-cycloalkyl, --CH.sub.2--C.sub.3-6-cycloalkyl, or bridged C.sub.3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halogen, lower alkyl

This application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application PCT/KR2008/003975, filed on Jul. 4, 2008, which claims priority to Korean Patent Application No. 10-2008-0064291, filed on Jul. 3, 2008 and Korean Patent Application No. 10-2007-0066887, filed on Jul.

FIELD OF THE INVENTION The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells.

BACKGROUND OF THE INVENTION The present invention relates to (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamide derivatives, and to pharmaceutical compositions and methods of treatment. The compounds of the present invention are inhibitors of zinc metalloendopeptidases, especially